webinar Archives - American College of Apothecaries

WEBINAR: Conquer Your Personal Coliseum by Developing Your Inner Gladiator

Terry Bondurant2024-10-23T16:10:34-05:00October 17th, 2024|Categories: Administration/Management, Webinar|Tags: pharmacist, Pharmacy Technician, webinar|

In celebration of American Pharmacists Month, ACA is offering this webinar free of charge for ACA and ACVP members. A limited number of complimentary registrations are available for non-members; additional registrations are available for $10.

Date and Time of Activity
Wednesday, October 23, 2024
1:30 pm EDT/ 12:30 pm CDT/ 11:30 am MDT/ 10:30 am PDT

In the fast-paced world of healthcare, personal development is essential for professional growth, especially for pharmacists and pharmacy technicians. However, many professionals in the field focus solely on clinical or business skills, often neglecting personal growth, which is key to long-term success and leadership.

This webinar will equip participants with practical strategies to conquer their own “personal coliseum” by developing the resilience and mindset of an inner gladiator. Attendees will explore key opportunities and barriers to personal growth, identify effective strategies for setting and achieving meaningful goals, and review literature-supported methods to enhance personal development.

At the completion of this activity, the participant will be able to:

Recognize opportunities for personal leadership development
Identify barriers to personal development
Identify strategies to improve personal development goal success.
Use key strategies to create a personal development goal as part of a personal development action plan.

Click Here to View Complete Activity Description

This high-energy session will supercharge you to step up as a dynamic leader, an unstoppable team player, and a top-tier patient care champion! Through focused personal development, you’ll gain the tools and mindset to break through barriers, unlock your full potential, and elevate your impact in every aspect of your career. Get ready to ignite your inner drive and lead like never before!

💥 Ready to unleash your inner gladiator? 💪

Save your seat now!

Loading…

The American College of Apothecaries (ACA) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACA has accredited this knowledge-based program for 1.0 contact hour (0.1 CEUs) of continuing education credit for pharmacists and pharmacy technicians.

Speaker: Dr. Jay Phipps, PharmD, MBA, FACA, FACVP

Dr. Jay Phipps, the Pharmacy Gladiator, is a Pharmacy Doctor, Entrepreneur, President, and CEO at Phipps Pharmacy. Phipps Pharmacy is an independent pharmacy who provides pharmacy doctor provided patient care including traditional dispensing, compounding services, long-term care pharmacy services, and tailor-made prescription compounding to patients in middle and west Tennessee. Dr. Jay is also the President and CEO of PhippsCare that focuses on Pharmacy Doctor provided healthcare and Health Insurance Solutions which specializes in medical and pharmacy insurance plans for seniors.

Dr. Jay received a Doctor of Pharmacy degree from The University of Tennessee Health Science Center where he also completed a residency in Drug Information and Pharmacotherapy. He also received an MBA in Strategy and Leadership from Indiana University – Kelley School of Business. Dr. Jay claimed the #2 spot in the 2023 Top 50 Most Influential Leaders in Pharmacy and has also been recognized by Union University as the Preceptor of the Year. Phipps Pharmacy was the recipient of the 2024 Good Neighbor Pharmacy Advocacy Champion and was recognized as the 2022 NCPA Innovation Center Excellence Award for Best Community Engagement.

WEBINAR: DSCSA—13 Year Implementation and 2024 Update

Terry Bondurant2024-09-10T10:07:47-05:00September 10th, 2024|Categories: Pharmacy Law, Regulatory Issues, Webinar|Tags: pharmacist, Pharmacy Technician, webinar|

Date and Time of Activity
Tuesday, October 1, 2024
11 am EDT/ 10 am CDT/ 9 am MDT/ 8 am PDT

Pharmacy professionals play a crucial role in protecting patient from drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.

Enacted in 2013, DSCSA is taking over 13 years to implement. Pharmacies need to prepare for the DSCSA requirements with a November 27, 2026 FDA enforcement implementation to receive or exchange transaction information electronically and conduct package level verification. The implementation of systems to produce serialized transaction information in a readily retrievable manner and develop SOPs for regulatory or trading partner transaction data requests will take time, and pharmacies should start today, if they have not already, to ensure compliance with the new enforcement implementation date. That said, despite the DSCSCA granting an exemption for small dispensers until November 27, 2026, pharmacies should be aware of their obligations to make appropriate purchases and maintain inventory purchase information in accordance with their Pharmacy Benefit Manager (“PBM”) Provider Manuals and Agreements. PBMs continue to audit pharmacies to ensure their sourcing of inventory is valid and despite any exemption granted by the DSCSA, such audit measures are expected to continue.

Activity Description:

In this webinar, we will review the phased in implementation and provide update of 2024 and beyond.

At the completion of this activity, the participant will be able to:

Identify the DSCSA requirements for receiving, validating, and storing DSCSA Transaction Information (TI) and Transaction Statements (TS).
Describe the procedures for implementing electronic operability at the package level for traceability.
Identify the regulatory requirements and documentation needed for compliance with audit records, inspections, and other inquiries.
Explain the processes for verifying product legitimacy, including methods for quarantining, investigating, and reporting suspect products.

Click Here to View Complete Activity Description

Don’t miss this opportunity to improve your ability to implement best practices to protect patients from drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.

Click below to register:

Speaker:

Martha M. Rumore, PharmD, Esq, MS, LLM, FAPhA is a pharmacist-attorney in Frier Levitt’s Life Sciences Department. She is also a registered patent attorney and leads the firm’s Intellectual property team. She has broad and in depth healthcare and regulatory experience. Her practice focuses on intellectual property (patents, trademarks, copyrights, trade secrets) and healthcare law, Food, Drug, Device & Cosmetic law (all facets-483s to clinical trials to registrations and product approval), pharmacy law and regulatory issues, 503A/503B compounding, Board of Pharmacy (licensing and disciplinary matters), PBM audits, and DSCSA supply chain compliance. Dr. Rumore has over 25 years of health-system, pharmaceutical industry, and law firm experience in the area of Food, Drug & Cosmetic Law and pharmaceutical intellectual property Dr. Rumore is fluent in cGMPs, GCPs, writing and reviewing Clinical Trial Agreements (CTAs), Investigator brochures, manuscripts, labeling & advertising review, NDAs, study reports, and documents for regulatory submissions. She often prepares legal memoranda on healthcare/FDA matters and conducts Mock State Board of Pharmacy and FDA inspections for compounding pharmacies. Dr. Rumore has practiced both pharmacy and law. She has actual experience as a compounding pharmacist. She regularly counsels on Section 503A and state-specific compounding requirements, assesses compounding practices for state and federal regulatory compliance, including USP 797/795/800, medical necessity documentation, advertising & promotion, reimbursement issues, infrastructure, and preparing compounding policies and procedures that provide clear guidelines, standards, and training for staff. Previously, she was at the Director level in Drug Regulatory Affairs/Compliance in the pharmaceutical industry and hospital pharmacy. She taught Pharmacy Law, Drug Regulatory Affairs, and Food Drug & Cosmetic Law at several New York Colleges of Pharmacy and currently teaches Food, Drug & Cosmetic Law at Maurice A. Deane School of Law at Hofstra University. She is a frequent lecturer and has over 200 publications and presentations.

ACA WEBINAR: Legal Insights into Peptide & Semaglutide Compounding: Navigating FDA, State Boards, and Telemedicine

Taisha Cunningham2024-10-01T12:01:25-05:00February 8th, 2024|Categories: compounding, Pharmacy Law, Regulatory Issues, Telemedicine / Telepharmacy|Tags: pharmacist, Pharmacy Technician, semaglutide, webinar|

Equip yourself with essential knowledge about the management and distribution of 503A compounded products, the intellectual property intricacies in peptide and semaglutide compounding, and understanding the FDCA and recent FDA guidance. Moreover, you will be able to assess the regulatory landscape effectively, ensuring your practices are in line with state laws and regulations.

Activity Description:

As the landscape of compounding peptides and semaglutide continues to evolve rapidly, a multitude of legal challenges and opportunities arise. This session aims to shed light on the pivotal developments and regulatory nuances in this dynamic sector. Our speakers will delve into critical topics such as the FDA’s current stance on peptide compounding, recent pronouncements from state Boards of Pharmacy, and the intricate legalities surrounding brand manufacturers. Additionally, the webinar will explore the burgeoning realm of telemedicine and its implications for compounders, along with guidance on navigating the complexities of bulk chemical ingredients.

Click Here to View Complete Activity Description

Don’t miss out on this opportunity to enhance your professional skills and understanding of semaglutide and peptide compounding!

Click below to register:

At the completion of this activity, the participant will be able to:

Discuss the management and distribution of 503A compounded products among DSCSA trading partners,
encompassing transfers, dispensing, and oversight by state Boards of Pharmacy, particularly focusing on
semaglutide and peptide compounding.
Evaluate the intricacies of intellectual property in peptide and semaglutide compounding and advertising.
Analyze the key aspects of the FDCA and recent FDA guidance on compounding peptides and semaglutide,
including the legal trends involving compound semaglutide, manufacturer enforcement efforts, and the impact
on telemedicine arrangements.
Assess the regulatory landscape by comparing state laws concerning pharmacies’ compensation and feesharing
with prescribing physicians, within the context of compounded semaglutide and telemedicine practices.

Speakers:

Martha M. Rumore, PharmD, Esq, MS, LLM, FAPhA is a pharmacist-attorney in Frier Levitt’s Life Sciences Department. Her practice focuses on healthcare law; Food, Drug Cosmetic law; pharmacy law and regulatory issues; PBM issues; as well as pharmaceutical and medical device intellectual property including trademark, copyright, trade secret and all aspects of patent law (due diligence, prosecution, opinion work, litigation, and transactional matters). Dr. Rumore has over 15 years of law firm experience in the area of Food, Drug & Cosmetic Law and pharmaceutical intellectual property, counseling on early market opportunities for pharmaceutical clients particularly in the area of ANDA and 510K applications and all facets of Paragraph IV litigation.

Matthew J. Modafferi, Esq is a seasoned litigation and trial attorney with experience in healthcare law. He focuses his practice on white collar defense and investigations, and complex civil litigation. As a Partner in Frier Levitt’s Healthcare and Life Sciences Litigation Department, Matthew’s practice is dedicated to representing healthcare clients in litigation matters including healthcare fraud, qui tam, and False Claims Act matters. Matthew also helps clients successfully navigate DEA inspections and investigations, state and federal OIG investigations, and government self-disclosures. Matthew previously worked as an Assistant United States Attorney in the Civil Division at the U.S. Attorney’s Office for the Eastern District of New York. During his time as a federal prosecutor, Matthew represented the United States and its agencies in various affirmative and defensive matters, appearing before both the Eastern District of New York and the Second Circuit Court of Appeals. He successfully defended Executive Branch policies and initiatives, and prosecuted health care fraud qui tam and other False Claims Act cases.